Payment overview · 2025
General Payments
$1,033.31
43 reported records · 12 companies
Healthcare provider profile · identity verified
Ilya Bilik, MD, FACP
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1093731374
Verified facts
What the public records show
CMS Open Payments records show Ilya Bilik, MD, FACP received $1,033.31 in general payments during 2025 across 43 reported records.
ABBVIE INC. accounted for 39.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Prolia, Rybelsus, Trelegy Ellipta, Ubrelvy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $406.81 | 39.4% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $115.27 | 11.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $112.21 | 10.9% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.52 | 8.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.24 | 6.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.64 | 6.1% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.83 | 5.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.10 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.25 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.16 | 2.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.40 | 2.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.88 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,033.31 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $234.80 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $172.01 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $134.60 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $90.82 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.82 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $87.11 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $84.77 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $82.52 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $62.64 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $55.83 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.87 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.87 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.91 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.10 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.16 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 180 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 281 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 114 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 308 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
180 | 40 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
308 | 46 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
175 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
281 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
281 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 863 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 799 | 156 |
| Atorvastatin Calcium | Atorvastatin Calcium | 769 | 168 |
| Metoprolol Succinate | Metoprolol Succinate | 722 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 425 | 76 |
| Losartan Potassium | Losartan Potassium | 398 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 391 | 66 |
| Metformin Hcl | Metformin Hcl | 386 | 78 |
| Omeprazole | Omeprazole | 330 | 63 |
| Linzess | Linaclotide | 308 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 304 | 67 |
| Famotidine | Famotidine | 300 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 298 | 53 |
| Eliquis | Apixaban | 281 | 47 |
| Vascepa | Icosapent Ethyl | 278 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 59 |
| Simvastatin | Simvastatin | 243 | 44 |
| Atenolol | Atenolol | 240 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 239 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 235 | 45 |
| Valsartan | Valsartan | 231 | 41 |
| Nifedipine Er | Nifedipine | 230 | 36 |
| Furosemide | Furosemide | 224 | 47 |
| Nebivolol Hcl | Nebivolol Hcl | 214 | 34 |
| Metformin Hcl Er | Metformin Hcl | 203 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 181 | 30 |
| Creon | Lipase/Protease/Amylase | 180 | 40 |
| Synthroid | Levothyroxine Sodium | 175 | 28 |
| Carvedilol | Carvedilol | 172 | 30 |
| Dexlansoprazole Dr | Dexlansoprazole | 170 | 26 |
| Lidocaine | Lidocaine | 160 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 159 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 51 |
| Lisinopril | Lisinopril | 152 | 30 |
| Enalapril Maleate | Enalapril Maleate | 151 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 33 |
| Gabapentin | Gabapentin | 148 | 39 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 141 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 35 |
| Finasteride | Finasteride | 139 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 135 | 29 |
| Januvia | Sitagliptin Phosphate | 134 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 26 |
| Allopurinol | Allopurinol | 126 | 26 |
| Ketoconazole | Ketoconazole | 122 | 24 |
| Jardiance | Empagliflozin | 114 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 113 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 103 | 18 |
| Montelukast Sodium | Montelukast Sodium | 99 | 23 |
| Azithromycin | Azithromycin | 97 | 80 |
| Ezetimibe | Ezetimibe | 90 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 18 |
| Zenpep | Lipase/Protease/Amylase | 85 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 77 | 19 |
| Ozempic | Semaglutide | 77 | 18 |
| Ramipril | Ramipril | 72 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 71 | suppressed |
| Glimepiride | Glimepiride | 70 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | suppressed |
| Tradjenta | Linagliptin | 68 | suppressed |
| Dexilant | Dexlansoprazole | 67 | 11 |
| Myrbetriq | Mirabegron | 64 | suppressed |
| Mounjaro | Tirzepatide | 63 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 62 | 21 |
| Clonidine Hcl | Clonidine Hcl | 59 | 13 |
| Mometasone Furoate | Mometasone Furoate | 59 | 18 |
| Alendronate Sodium | Alendronate Sodium | 57 | suppressed |
| Entresto | Sacubitril/Valsartan | 57 | 11 |
| Glipizide Er | Glipizide | 57 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 56 | 17 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 56 | suppressed |
| Celecoxib | Celecoxib | 55 | 11 |
| Dutasteride | Dutasteride | 54 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 53 | 13 |
| Potassium Chloride | Potassium Chloride | 51 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 43 |
| Hydrocortisone | Hydrocortisone | 47 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 47 | suppressed |
| Nexium | Esomeprazole Magnesium | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 36 |
| Glipizide | Glipizide | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 45 | 16 |
| Clotrimazole | Clotrimazole | 44 | 15 |
| Ibuprofen | Ibuprofen | 44 | 22 |
| Meloxicam | Meloxicam | 44 | 21 |
| Mupirocin | Mupirocin | 44 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 43 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 43 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 12 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 42 | suppressed |
| Telmisartan | Telmisartan | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | 12 |
| Ranolazine Er | Ranolazine | 40 | suppressed |
| Alprazolam | Alprazolam | 39 | 14 |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Irbesartan | Irbesartan | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Restasis | Cyclosporine | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 15 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Nadolol | Nadolol | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Crestor | Rosuvastatin Calcium | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 34 | 12 |
| Sucralfate | Sucralfate | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | 11 |
| Procto-Med Hc | Hydrocortisone | 25 | suppressed |
| Ursodiol | Ursodiol | 25 | suppressed |
| Edarbi | Azilsartan Medoxomil | 24 | suppressed |
| Prednisone | Prednisone | 24 | 22 |
| Alcohol Swab | Alcohol Antiseptic Pads | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Opzelura | Ruxolitinib Phosphate | 23 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 22 | suppressed |
| Ciclopirox | Ciclopirox | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Ssd | Silver Sulfadiazine | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Invokana | Canagliflozin | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Bystolic | Nebivolol Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | 11 |
| Metronidazole | Metronidazole | 16 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Savaysa | Edoxaban Tosylate | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ivermectin | Ivermectin | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Rapaflo | Silodosin | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Bicillin L-A | Penicillin G Benzathine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 11 | suppressed |
| Exforge | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,033.31 · 43 records | ABBVIE INC. | ABRYSVO, COMIRNATY, CREON, ELIQUIS, EVENITY, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Veozah, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error